Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy.
暂无分享,去创建一个
W. Borkowsky | W. Bellini | M. Levin | S. Pelton | M. Abzug | S. Nachman | H. Rosenblatt | T. Fenton | J. Beeler | S. Audet | S. B. Sowers | Min Qin
[1] A. Fowlkes,et al. Persistence of vaccine-induced measles antibody beyond age 12 months: a comparison of response to one and two doses of Edmonston-Zagreb measles vaccine among HIV-infected and uninfected children in Malawi. , 2011, The Journal of infectious diseases.
[2] F. Chiodi,et al. Measles Outbreak in Africa—Is There a Link to the HIV-1 Epidemic? , 2011, PLoS pathogens.
[3] W. Moss,et al. The urgent need for recommendations on revaccination of HIV-infected children after successful antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] W. Moss,et al. Do children infected with HIV receiving HAART need to be revaccinated? , 2010, The Lancet. Infectious diseases.
[5] L. Aurpibul,et al. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] L. Aurpibul,et al. MEASLES OUTBREAK IN AN ORPHANAGE: HIV-INFECTED CHILDREN ON ANTIRETROVIRAL THERAPY ARE STILL AT RISK , 2010, The Pediatric infectious disease journal.
[7] G. Ruiz-Palacios,et al. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART. , 2009, Vaccine.
[8] T. Quinn,et al. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. , 2009, The Journal of infectious diseases.
[9] W. Borkowsky,et al. Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy. , 2009, The Journal of infectious diseases.
[10] P. Palma,et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children , 2009, Proceedings of the National Academy of Sciences.
[11] S. Pelton,et al. Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox. , 2009, The Journal of infectious diseases.
[12] N. Haigwood,et al. Immune Responses to Measles and Tetanus Vaccines Among Kenyan Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Children Pre- and Post-Highly Active Antiretroviral Therapy and Revaccination , 2009, The Pediatric infectious disease journal.
[13] A. Fowlkes,et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. , 2008, The Journal of infectious diseases.
[14] J. Mossong,et al. Predicted impact of the HIV-1 epidemic on measles in developing countries: results from a dynamic age-structured model. , 2008, International journal of epidemiology.
[15] T. Quinn,et al. HIV type 1 infection is a risk factor for mortality in hospitalized Zambian children with measles. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] N. Andrews,et al. Plaque reduction neutralization test for measles antibodies: Description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. , 2007, Vaccine.
[17] F. Tangy,et al. HIV-Infected Children Living in Central Africa Have Low Persistence of Antibodies to Vaccines Used in the Expanded Program on Immunization , 2007, PloS one.
[18] W. Borkowsky,et al. Pertussis Booster Vaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy , 2007, Pediatrics.
[19] L. Aurpibul,et al. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] T. Quinn,et al. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study. , 2007, The Journal of infectious diseases.
[21] W. Borkowsky,et al. Immunogenicity, Safety, and Predictors of Response After a Pneumococcal Conjugate and Pneumococcal Polysaccharide Vaccine Series in Human Immunodeficiency Virus-Infected Children Receiving Highly Active Antiretroviral Therapy , 2006, The Pediatric infectious disease journal.
[22] T. Kuijpers,et al. Persistent Humoral Immune Defect in Highly Active Antiretroviral Therapy–Treated Children With HIV-1 Infection: Loss of Specific Antibodies Against Attenuated Vaccine Strains and Natural Viral Infection , 2006, Pediatrics.
[23] M. Levin,et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. , 2006, The Journal of infectious diseases.
[24] W. Bellini,et al. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. , 2004, The Journal of infectious diseases.
[25] K. Mohan,et al. Response to immunization with measles, tetanus, and Haemophilus influenzae type b vaccines in children who have human immunodeficiency virus type 1 infection and are treated with highly active antiretroviral therapy. , 2003, Pediatrics.
[26] N. Amodei,et al. Hemophilia Growth and Development Study: caregiver report of youth and family adjustment to HIV disease and immunologic compromise. , 2003, Journal of pediatric psychology.
[27] C. Chan,et al. Immunization of HIV-infected children with varicella vaccine. , 2001, The Journal of pediatrics.
[28] J. Englund,et al. Effect of highly active antiretroviral therapy on the serological response to additional measles vaccinations in human immunodeficiency virus-infected children. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] E. Mahoney,et al. Response to measles, mumps, and rubella revaccination among HIV‐positive and HIV‐negative children and adolescents with hemophilia , 2001, American journal of hematology.
[30] K. Ruxrungtham,et al. Immune responses to measles immunization and the impacts on HIV-infected children. , 2000, The Southeast Asian journal of tropical medicine and public health.
[31] W. Bellini,et al. Measles antibody in vaccinated human immunodeficiency virus type 1-infected children. , 1996, Pediatrics.
[32] E. Daar,et al. Abnormalities of measles antibody response in human immunodeficiency virus type 1 (HIV-1) infection. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[33] K. Mcintosh,et al. Decline of measles antibody titers after immunization in human immunodeficiency virus-infected children. , 1995, The Pediatric infectious disease journal.
[34] W. Bellini,et al. Measles immunity in HIV-infected children. , 1994, Pediatric AIDS and HIV infection.
[35] J. Pinto-Martin,et al. Responses to measles immunization in children infected with human immunodeficiency virus. , 1994, The Journal of pediatrics.
[36] S. Pelton,et al. Antibody response to measles and rubella vaccine by children with HIV infection. , 1993, Journal of acquired immune deficiency syndromes.
[37] E. Connor,et al. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. , 1992, The Pediatric infectious disease journal.
[38] L. Kaplan,et al. Severe measles in immunocompromised patients. , 1992, JAMA.
[39] Robert T. Chen,et al. Measles antibody: reevaluation of protective titers. , 1990, The Journal of infectious diseases.
[40] W. Borkowsky,et al. Measles and measles immunity in children infected with human immunodeficiency virus. , 1989, JAMA.
[41] P. Albrecht,et al. Role of virus strain in conventional and enhanced measles plaque neutralization test. , 1981, Journal of virological methods.